DLL3
42 programs · 41 companies
Programs
42
Companies
41
Active Trials
34
Targeting DLL3
| Drug | Company | Phase | MOA | Indications |
|---|---|---|---|---|
| PFE-7809 | Pfizer | Phase 1 | Huntington's | |
| Pexarelsin | AstraZeneca | Phase 1 | CMLFL | |
| Zorivorutinib | Bristol-Myers Squibb | Approved | Prostate CaMM | |
| Zenonesiran | GSK | Preclinical | DMDHemophilia A | |
| AMG-7379 | Amgen | Preclinical | MGDravet | |
| ARG-1924 | Argenx | Preclinical | SMADLBCL | |
| Cevinaritide | Genmab | Phase 2/3 | CTCL | |
| RCU-6379 | Arcus Bio | Phase 1/2 | OCDLGS | |
| RPT-8672 | Repare | Phase 2 | Psoriasis | |
| Nirabrutinib | Astellas | Phase 2 | AS | |
| Tirainavolisib | Chugai | Approved | PBC | |
| SUN-5027 | Sun Pharma | Preclinical | PompeRSV | |
| CHI-IIT-162 | Children's Oncology Grp | Preclinical | CML | |
| Zoribrutinib | Prometheus (Merck) | Phase 1/2 | MCLMigraine | |
| Olpazasiran | Prometheus (Merck) | Preclinical | ADHDTTR Amyloidosis | |
| Mirinesiran | Boundless Bio | Phase 3 | MS | |
| Miricapivasertib | Aerovate Ther | NDA/BLA | EoENASH | |
| COR-899 | Correvio (Advanz) | Phase 2/3 | RBPAH | |
| Olpasertib | Diffusion Pharma | Phase 3 | NBOCD | |
| Zorizumab | Cirius Therapeutics | Phase 1 | SCLC | |
| Adagraosocimab | Spire Biotech | Preclinical | Parkinson'sHS | |
| Polatenlimab | Caris Life Sciences | NDA/BLA | Migraine | |
| KNS-1946 | Kiniksa Pharma | Phase 3 | MyelofibrosisRett | |
| Tezesotorasib | Volato Group | Phase 2/3 | TTR AmyloidosisProstate Ca | |
| Pexaglumide | Agora Inc | Phase 1/2 | CKDNASH | |
| DAS-6981 | Dasan Zhone | Phase 2/3 | MMPSP | |
| KAR-2338 | Kartos | Preclinical | CRC | |
| Lirafotisoran | Askbio (Bayer) | Preclinical | DLBCL | |
| 415-4068 | Kyowa Kirin | NDA/BLA | NB | |
| Lisotenlimab | Y-Biologics | Phase 1/2 | AS | |
| Ivolemzoparlimab | Clover Bio | Approved | Bladder CaHS | |
| Zanumavacamten | Dechra Pharma | Phase 1/2 | DravetAS | |
| CIR-2997 | Circassia | Phase 2/3 | SCLC | |
| 654-1692 | Medigen Vac | Phase 2 | PNHPsoriasis | |
| NEO-1781 | NeoGenomics | NDA/BLA | Heart FailureBladder Ca | |
| Poladerotide | Oasmia | Phase 3 | CMLPAH | |
| Miriratamab | Cadila Healthcare | NDA/BLA | LN | |
| Mavumavacamten | Kalbe Farma | Phase 3 | MDS | |
| AIP-1890 | Adcock Ingram | Phase 3 | GAPompe | |
| BEA-2267 | Beacon Pharma | Phase 3 | Huntington's | |
| BRK-7538 | Bruker | Phase 2/3 | Endometrial CaCholangiocarcinoma | |
| Miriosocimab | IDEXX Laboratories | Approved | Pompe |